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Abstract: Patients with obesity and type 2 diabetes mellitus (T2DM) are regarded to have reduced 
serum magnesium (Mg) concentrations. We aimed to assess the changes in serum Mg concentrations at 
12-month follow-up in patients, with and without T2DM, who underwent one anastomosis gastric 
bypass surgery. Overall, 50 patients (80% female, age 42.2 (12.5) years) with morbid obesity (mean 
baseline BMI 43.8 (4.3) kg/m2) were included in the analysis. Half of the included patients had T2DM 
diagnosed at baseline, and these patients showed lower serum Mg concentration (0.78 (0.07)) vs. 0.83 
(0.05) mmol/L; p = 0.006), higher blood glucose levels (129.9 (41.3) vs. 87.6 (8.1) mg/dL; p < 0.001) as well 
as HbA1c concentrations (6.7 (1.4) vs. 5.3 (0.5)%; p < 0.001). During follow-up, BMI and glucose levels 
showed a decrease; however, serum Mg levels remained stable. At baseline 42% of patients were 
found to be Mg deficient, which was reduced to 33% at six months and to 30% at 12 months follow-
up. Moreover, patients with T2DM had an odds ratio of 9.5 (95% CI = 3.0–29.7; p < 0.001) for 
magnesium deficiency when compared to patients without T2DM. Further research into the role of 
Mg and its role in T2DM and other obesity-related comorbidities are needed. 
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1. Introduction 
Magnesium (Mg) is the second most abundant intracellular electrolyte serving as a co-factor in over 
300 different enzymatic and biochemical reactions responsible for normal functioning of the organism [1–
3]. It is also involved in blood glucose control, given its vital role in activating the beta-subunit of the 
insulin receptors [4]. However, taking into account the multitude of processes in which Mg is 
involved with, the physiological homeostasis of Mg is still not well understood [4,5]. 
Mg is present in both animal and plant based foods, with legumes, nuts, grains, seeds, and green 
leafy vegetables presenting the richest sources [6]. However, even with the relatively broad distribution 
of foods containing Mg, studies have indicated that intake of Mg is suboptimal, i.e., not reaching the 
recommended daily intake [7]. An analysis of nationally representative data from the United States 
showed that more than 80% of Americans do not meet the recommended daily intake with older 
African Americans showing the lowest Mg intake compared to other ethnic groups [8]. 
Reduced serum Mg (hypomagnesemia) has also been reported in patients with obesity, diabetes, and 
hypertension, and has been suggested as a biomarker for the symptoms cascade leading to the 
metabolic syndrome [9,10]. Studies reported that men with low serum Mg values had a two-fold 
increase in the incidence of type 2 diabetes mellitus (T2DM), while those in the highest quintile of Mg 
intake can reduce their diabetes risk by more than 30%. The exact mechanism by which 
hypomagnesemia induces or worsens T2DM is unclear, however, both secretion and action of insulin 
seem to be affected [11]. A possible mechanism could be the decreased renal Mg reabsorption as a 
consequence of insulin deficiency [11] or concomitant use of medications such as proton pump 
inhibitors, diuretics, statins, and antimicrobial agents [12]. 
The increasing disease burden of obesity and the increase in its worldwide prevalence presents a 
major public health issue [13]. The Austrian Health Interview Survey (AT-HIS) in 2014 included adults 
from a representative sample of the Austrian population. Overall, 15,771 individuals were interviewed 
and 56% were female. In this sample, 33% of the adults were overweighed (male 40%, female 26%) 
and 14% were obese (male 16%, female 13%) [14]. Consecutively, lasting therapeutic effects can only 
be achieved through weight loss, as it is associated with improved metabolic function as well as 
decrease in risk of comorbidities [15,16]. Weight loss can be achieved through various lifestyle 
interventions, such as increasing physical activity levels and controlling caloric intake. However, in 
morbidly obese patients bariatric surgery is preferred since it is associated with long term weight loss 
and reduced prevalence of comorbidities [17]. According to the 4th Global Registry Report of the 
International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) from 2018, 1255 
bariatric surgeries have been reported in Austria between 2014–2018, and more than third preformed 
were the one anastomosis gastric bypass and mini-gastric bypass, making them a group of most 
commonly done bariatric surgeries in Austria [18]. 
Studies on obese patients following weight loss have reported inconsistent results, with some 
finding improvements in serum Mg levels and some reporting no changes in diabetic and non-diabetic 
patients with obesity [5,19,20]. As Mg has been linked to a myriad of positive health outcomes [21], and 
in light of rising trends in global obesity prevalence, our study aimed to investigate changes in serum 
Mg levels in patients with and without diabetes mellitus who underwent one-anastomosis gastric 
bypass (OAGB) before and after a 12-month follow-up. To our knowledge, this is the first study 
looking into Mg serum concentration of a patient cohort after this type of bariatric surgery. 
2. Materials and Methods 
2.1. Study Design 
This study is a secondary analysis of the data and blood samples of participants who had been 
enrolled in the LOAD-study (“Link between Obesity And Vitamin D”), a six-months double-blind, 
placebo-controlled, randomized trial of vitamin D supplementation. The primary aim of the LOAD-
study was to examine the efficacy and safety of a forced vitamin D regimen versus conventional 
supplementation on parameters of vitamin D metabolism in morbidly obese, vitamin D-deficient 
patients undergoing OAGB [22]. Inclusion criteria were; planned one-anastomosis gastric bypass 
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(OAGB) surgery, above 18 years old, 25-hydroxy-vitamin D (25(OH)D) serum concentrations of below 
75 nmol/L, no vitamin D supplementation, and a body weight below 140 kg (due to body weight 
limitation of the dual energy X-ray absorptiometry). Specific exclusion criteria included any other 
planned form of bariatric surgery than OAGB, hypo- and hypercalcemia, renal insufficiency, or 
primary hyperparathyroidism. In the first six months after OAGB surgery, the intervention group 
received the following vitamin D dosing regimen: Up to three oral loading doses of each 100,000 IU 
in the first month postoperatively, followed by maintenance dose of 3420 IU/day; and the control group 
received conventional supplementation (placebo in the first month with following maintenance doses of 
3420 IU/day). Afterwards, both groups were recommended to continue the vitamin D3 supplementation 
until the follow-up visit at 12 months. The details on design, the used materials and methods, as well 
as the sample size calculation of the LOAD-study, have been previously published [23]. Primary analysis 
included the repeated-measures analysis of covariance (ANCOVA) using random error (linear mixed 
model) to assess the effects of time and the interaction for changes in parameters between the groups 
by using different covariance structure models as appropriate, and were adjusted for age, sex, and 
baseline values. 
All OAGB procedures were performed at the General Hospital Vienna, Medical University of 
Vienna by the same surgical team using a laparoscopic approach. It is a simplified procedure that 
consists of a unique gastrojejunal anastomosis between a 30 to 40 mL sleeve gastric pouch and a jejunal 
omega-loop of approximately 200 cm [24]. The study methods are in accordance with the CONSORT 
(Consolidated Standards Of Reporting Trials) guidelines for reporting randomized trials [25]. 
This study was approved by the local Ethics Committee of the Medical University of Vienna (No° 
1899/2013), by the Austrian Competent Authority (No° LCM-718280-0001), registered at clinicaltrials.gov 
(Identifier: NCT02092376) and EudraCT (Identifier: 2013-003546-16), complies with the Declaration 
of Helsinki [26], and conducted from April 2014 to June 2016 at the Medical University of Vienna. 
The study participants were scheduled for OAGB surgery and all of them gave written informed 
consent preoperatively. 
2.2. Assessment of Variables 
Data were assessed before surgery (T0), at 6 months (T6), and at 12 months postoperatively 
(T12). At T0, age, sex, and medical history (e.g., comorbidities, prescribed medication) were collected 
as previously described [23]. Height and body weight (measured with the calibrated scale seca mBCA 
515) were obtained for each participant at the three time points. 
Blood samples were collected and serum Mg, glucose, HbA1c, triglycerides, total cholesterol, 
HDL cholesterol, and LDL cholesterol were used for this secondary analysis. 
2.3. Statistical Analysis 
The results are expressed as mean (standard deviation) for continuous and as percentages for 
categorical variables. In order to test for normal distribution, a visual test (histograms and box plots) 
was used and the Kolmogorov-Smirnov test was applied in addition. 
At baseline the difference between diabetic patients and parameters such as sex, age, BMI, glucose, 
HbA1c, oral antidiabetic drugs (OAD) and insulin use, serum lipid levels such as triglycerides, total 
cholesterol, HDL cholesterol, cholesterol/HDL ratio, and LDL cholesterol was assessed with t-test and 
Chi2-test. The statistical association between serum Mg and parameters such as diabetes mellitus, 
glucose, HbA1c, and serum lipid levels was examined by Pearson correlation coefficients. 
The main outcome of interest was the change in serum Mg concentration in the first postoperative 
year. Moreover, the changes in BMI, blood sugar levels, and serum lipid levels were also assessed. 
We used the entire sample for this analysis. We applied repeated-measures analysis of covariance 
(ANCOVA) using random error (linear mixed model) to assess the effect of time by using different 
covariance structure models as appropriate and which were adjusted for age, sex, and baseline values to 
supply an unbiased estimate of the mean difference [27]. A post hoc analysis with Bonferroni 
correction was used. 
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Estimates of the prevalence of Mg deficiency over time were calculated using generalized 
estimating equation (GEE) with a logit link function for binary outcomes and unstructured covariance 
matrices. With this approach, we examined effects with time as repeated factor with Mg deficiency 
as dependent variable, adjusted for age and sex. 
Means were compared unadjusted without imputation of missing data. All statistical analyses 
were performed with IBM® SPSS® Statistics for Windows, Version 23 software (IBM Corporation, 
Armonk, NY, USA). p-values < 0.05 were considered statistically significant and all tests were two-sided. 
3. Results 
3.1. Patients’ Characteristics 
Out of 67 eligible patients, 17 declined to participate (25%). The remaining 50 patients entered the 
randomized controlled trial [22]. Baseline characteristics are demonstrated in Table 1. Fifty percent of 
the patients suffered from type 2 diabetes mellitus (T2DM) and 22% of the patients used statins or 
fibrates. Diabetic patients and patients using statins/fibrates were significantly older. Two-thirds of 
the diabetic patients and over 90% of patients using statins/fibrates had an Mg deficiency. Serum lipid 
levels were not significant between diabetic and non-diabetic patients. 
Table 1. Patients’ characteristics. 
Parameters 
Total 
Type 2 Diabetes Mellitus 
p-Value + no (n = 25) yes (n = 25) 
Mean ± SD  
Number (%) 
Mean ± SD 
Number (%) 
Mean ± SD 
Number (%) 
Female 40 (80) 19 (76) 21 (84) 0.480 
Age (years) 42.2 ± 12.5 35.6 ± 11.9 48.8 ± 9.3 <0.001 
BMI (kg/m2) 43.8 ± 4.3 43.7 ± 4.9 43.9 ± 3.7 0.835 
Supplementation     
Vitamin D 8 (16) 3 (12) 5 (20) 0.440 
Iron 1 (2) 0 (0) 1 (4) 0.312 
Diuretics use 12 (24) 2 (8) 10 (40) 0.008 
Magnesium (mmol/L) 0.81 ± 0.07 0.83 ± 0.05 0.78 ± 0.07 0.006 
Deficient (<0.8 mmol/L) 21 (42) 5 (20) 16 (64) 0.002 
Glucose (mg/dL) 108.7 ± 36.4 87.6 ± 8.1 129.9 ± 41.3 <0.001 
HbA1c (%) 6.0 ± 1.3 5.3 ± 0.5 6.7 ± 1.4 <0.001 
OAD use 9 (18) 0 (0) 9 (36) 0.001 
Insulin use  6 (12) 0 (0) 6 (24) 0.009 
Triglycerides (mg/dL) 155.8 ± 79.8 164.5 ± 89.4 147.2 ± 69.6 0.447 
Total cholesterol (mg/dL) 198.2 ± 46.9 197.6 ± 31.9 198.9 ± 59 0.920 
HDL cholesterol (mg/dL) 47.3 ± 12.3 46.3 ± 10.3 48.2 ± 14.1 0.578 
Cholesterol/HDL ratio 4.4 ± 1.2 4.5 ± 1.3 4.3 ± 1.2 0.573 
LDL cholesterol (mg/dL) 120.6 ± 40.3 120 ± 29.9 121.2 ± 48.9 0.916 
Body Mass Index (BMI), Hemoglobin A1c (HbA1c), Oral antidiabetic drugs (OAD), High density 
lipoprotein (HDL), Low density lipoprotein (LDL), + T-test or Chi2-test. A p-value in bold denotes a 
significant difference (p < 0.05). 
There was a statistically significant association between serum Mg and T2DM (r = −0.38, p = 0.006), 
glucose (r = −0.42, p = 0.002), HbA1c (r = −0.52, p < 0.001) and statin/fibrate use (r = −0.48, p < 0.001). There 
was no statistically significant association between serum Mg and serum lipid levels. 
3.2. Associations between Diabetic Patients and Serum Magnesium, Blood Glucose and Serum Lipid 
Parameters in the First Postoperative Year 
As this study is a secondary analysis of the LOAD-study, a post hoc power calculation was 
applied for the main outcome (change in serum Mg concentration). This power analysis showed that 
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the current study had a power of 83% (α = 0.05) to detect differences in the mean serum Mg 
concentration between non-diabetics (n = 25) and diabetics (n = 25) after 12 months. 
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Table 2. Change in BMI, serum magnesium, glucose, and lipid parameters over time in diabetic and non-diabetic patients. 
Parameters 
Baseline 
p-Value + 
6 Months 
p-Value + 
12 Months 
p-Value + p-Value Group + 
p-Value 
Time + 
p-Value 
Group * Time + Mean ± SD Mean ± SD Mean ± SD 
BMI (kg/m2) 
Non-diabetics 43.7 ± 4.9 
0.504 
32.0 ± 3.8 0.020 28.0 ± 4.2 0.001 0.004 <0.001 0.001 
Diabetics 43.9 ± 3.7 32.4 ± 3.9 29.0 ± 2.5 
Magnesium (mmol/L) 
Non-diabetics 0.83 ± 0.05 0.006 0.84 ± 0.04 0.350 0.84 ± 0.05 0.248 0.033 0.286 0.474 
Diabetics 0.78 ± 0.07 0.78 ± 0.05 0.78 ± 0.09 
Glucose (mg/dL) Non-diabetics 87.6 ± 8.1 <0.001 83.5 ± 5.5 0.029 82.2 ± 5.8 0.019 <0.001 0.001 0.733 
Diabetics 129.9 ± 41.3 134.6 ± 26.5 131 ± 25.7 
HbA1c (%) 
Non-diabetics 5.3 ± 0.5 
0.001 
5.1 ± 0.3 
0.006 
5.1 ± 0.4 
0.057 0.264 <0.001 <0.001 
Diabetics 6.7 ± 1.4 6.2 ± 0.7 6.4 ± 0.8 
Triglycerides (mg/dL) 
Non-diabetics 164.5 ± 89.4 
0.072 
91.3 ± 29.8 
0.018 
85.3 ± 34.9 
0.643 0.453 <0.001 0.007 
Diabetics 147.2 ± 69.6 144.2 ± 30.6 104.6 ± 23.2 
Total cholesterol 
(mg/dL) 
Non-diabetics 197.6 ± 31.9 0.707 165.5 ± 38.7 0.507 163.7 ± 29.6 0.474 0.547 <0.001 0.604 
Diabetics 198.9 ± 59 170.5 ± 38.9 169.5 ± 56.1 
HDL cholesterol 
(mg/dL) 
Non-diabetics 46.3 ± 10.3 
0.324 
47.4 ± 10.2 
0.995 
53.8 ± 9.4 
0.303 0.301 <0.001 0.681 
Diabetics 48.2 ± 14.1 45.1 ± 8.9 55.1 ± 11.2 
Cholesterol/HDL 
ratio 
Non-diabetics 4.5 ± 1.3 
0.272 
3.6 ± 0.8 
0.761 
3.1 ± 0.8 
0.900 0.582 <0.001 0.726 Diabetics 4.3 ± 1.2 3.7 ± 0.7 3.1 ± 1.0 
LDL cholesterol 
(mg/dL) 
Non-diabetics 120 ± 29.9 
0.849 
99.8 ± 32.3 
0.971 
92.9 ± 24.9 
0.735 0.924 <0.001 0.916 
Diabetics 121.2 ± 48.9 96.5 ± 35.8 93.5 ± 52.1 
Body Mass Index (BMI), Hemoglobin A1c (HbA1c), High density lipoprotein (HDL), Low density lipoprotein (LDL). + Repeated measure analysis of variance and 
post hoc analysis with Bonferroni correction, adjusted for baseline value, age, and sex. A p-value in bold denotes a significant difference (p < 0.05).
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Table 2 shows the comparison between diabetic and non-diabetic patients on BMI, serum Mg, 
blood glucose, and serum lipid values over time. At T0, diabetic patients showed significantly lower 
serum Mg, and higher glucose and HbA1c concentrations. At T12, significant group differences in BMI 
and glucose values could be found. There were also between group differences in serum Mg 
concentration at T6 and at T12. In addition, BMI, HbA1c, and triglyceride values showed a significant 
group and time interaction, with higher concentrations in diabetic patients. 
Moreover, diabetic patients had an odds ratio of 9.5 (95% CI = 3.0, 29.7; p < 0.001) for Mg 
deficiency compared with non-diabetics, adjusted for age and sex. In total, Mg deficiency was found 
in 33% of the patients at T6 and 30% at T12. 
4. Discussion 
In our study of a cohort of patients with morbid obesity that underwent OAGB surgery, we 
found significantly lower serum Mg levels in patients with vs. without T2DM at baseline. This finding 
is in line with other studies confirming the association of low serum Mg and the presence of T2DM 
[5,19,20]. Insulin resistance and deficiency are considered to inhibit the reabsorption of Mg and 
accelerate its excretion through the kidneys [28]. Low levels of Mg in turn further decrease insulin 
sensitivity and the function of insulin receptors [29]. Overall, our patients with T2DM had an 8.5-fold 
greater risk of being Mg deficient compared to patients without T2DM. 
Regarding differences in Mg intake being the reason for low serum levels, a cross-sectional study 
in a Chinese population reported no significant associations between dietary Mg intake (evaluated 
using a semi-quantitative food frequency questionnaire) and T2DM prevalence [20]. Moreover, there 
was no correlation between dietary Mg intake and serum concentrations in participants with diabetes. 
These results are similar to those of other studies emerging from Asia. In contrast, some investigators 
reported a significantly inverse correlation between dietary Mg and diabetes [30–32]. This may be due 
to difference in the degree of insulin resistance in the Asian population in comparison to Western 
population [33]. Further differences may be found in the dietary patterns, as a study using US nationally 
representative data found differences among different ethnic groups and their overall Mg intake [8]. 
However, this study did not specifically investigate the Asian population in the US due to a lack of data. 
These results are contradicted by a recent umbrella review of observational and intervention studies 
indicating that, out of 55 independent outcomes associated with Mg levels, there was highly suggestive 
evidence that higher Mg intake at baseline was associated with lower T2DM incidence [21]. The authors 
of this umbrella review acknowledge that there is a possible bias in observational studies, since higher 
Mg intake might be associated with a healthier lifestyle and dietary patterns. There is also a rather weak 
evidence that Mg supplementation is able to significantly improve the results of the 2 h oral glucose 
tolerance test in high risk groups for T2DM. Review studies indicated that more randomized 
controlled trials focusing on different age groups, as well as factors like metabolic control and 
baseline Mg, are needed in order to provide recommendations on the supplementation of Mg in 
patients with diabetes [34]. 
After OAGB surgery, there was a continuous drop in BMI in all patients, which was significantly 
greater in nondiabetic subjects at 6 and 12 months follow-up. Differences remained significant after 
adjusting for age, gender, and baseline values, and showed a significant group-time interaction. 
However, the drop in BMI was not followed by changes in the serum Mg concentrations. Both groups 
showed no changes in mean concentrations of serum Mg throughout the study. A 2009 study by 
Johansson et al. examined 21 patients without diabetes after Roux-en-Y gastric bypass surgery [35]. 
They reported lower plasma glucose and increased serum Mg levels. Similarly, a 2019 study by 
Mikalsen Meyer et al. [19] showed that a modest weight loss of about ten kilograms in obese patients 
with lifestyle interventions already increased serum Mg levels in obese patients with and without 
T2DM by around 5%. After Roux-en-Y gastric bypass surgery, the serum Mg concentrations 
continued to rise in patients with T2DM and remained stable in non-diabetic patients [19]. 
Some differences for the controversial findings may arise from surgical techniques, as different 
techniques are associated with different effects on serum Mg concentrations. An analysis of patients 
after Roux-en-Y gastric bypass surgery found that 32% of patients were Mg deficient. The results 
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showed a mild increase in Mg levels following surgery after two years follow-up and no changes in 
mean values of serum Mg concentration at time of the analysis (in mean almost seven years after 
intervention) [36]. These results are similar as we also found 33% and 30% at 6 and 12 months after 
surgery, respectively. 
This secondary analysis is limited by a rather small sample size that was based on sample size-
calculations taking into consideration serum differences of vitamin D concentration. However, as we 
show significant differences, the sample size calculation can be considered valid. The study is 
comprised of over 80% women, which is expected in a patient population undergoing bariatric 
surgery, but prohibits generalizations to male patients. Moreover, there is no gold standard in 
determining Mg status. The strengths of the study include detailed pre- and post-operative data of 
patients undertaking OAGB, a relatively new surgical procedure that has not been evaluated in 
regards to Mg serum concentrations. 
5. Conclusions 
In our patients with obesity, we observed significantly lower serum Mg levels in patients with vs. 
those without T2DM. Following bariatric surgery and weight loss, Mg serum concentrations remained 
stable. Since low Mg levels are associated with hypertension, oxidative stress, and coronary heart 
disease [9], it is possible that normalized Mg levels could reduce the risk of comorbidities associated 
with obesity and T2DM, which, however, needs to be proven. 
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